CARBOHYDRATE METABOLISM DISTURBANCES: THERAPEUTIC POTENTIAL IN METABOLIC SYNDROME
Abstract
The study was focused on dibicor effects on carbohydrate metabolism (CM) and insulin resistance (IR) in patients with metabolic syndrome (MS), as well as the correlations between various CM parameters, chronic heart failure (CHF), and abdominal obesity (AO). In total, 61 patients aged 31–66 years gave their informed consent to participate in the study, including 21,7% of men and 78,3% of women. The control group (n=30) received standard therapy only, while the main group (n=30) also received dibicor. All participants underwent anthropometry, blood pressure and IR measurement, lipid and carbohydrate metabolism assessment. Twelve-month dibicor therapy was associated with improved CM and reduced IR. Functional class (FC) of CHF directly correlated with CM disturbance severity, while AO correlated with fasting and glucose tolerance test levels of plasma glucose. In MS and CHF, dibicor improved CM, reduced IR, and therefore, facilitated the CHF FC reduction.
About the Authors
I. V. Kryuchkova
Кубанский государственный медицинский университет, кафедра пропедевтики внутренних болезней, Краснодар
Russian Federation
Russian Federation
A. S. Adamchik
Кубанский государственный медицинский университет, кафедра пропедевтики внутренних болезней, Краснодар
Russian Federation
Russian Federation
References
1. Беляков Н.А., Чубриева С.Ю. Метаболический синдром и атеросклероз.//Медицинский академический журнал. 2007. Т.7. № 1. С.45 – 59.
2. Маколкин В.И. Необходимость гликемического контроля при лечении метаболического синдрома.//Consilium medicum. 2007. Т.9. № 5. С.58 – 62.
3. Оганов Р., Мамедов М., Колтунов И. Метаболический синдром: путь от научной концепции до клинического диагноза. // Врач.2007. № 3. С. 3 – 7.
4. Российские национальные Рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Москва, 2007г.-76с.
5. Чибисов С.М., Рапопорт С.И., Колесников Д.Б. и др. Метаболический синдром: больше вопросов, чем ответов.// Клиническая медицина. 2008. № 6. С.30 – 35.
6. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of Higt Blood Cholesterol in Adults (Adult Treatment Panel III)// JAMA 2001; 285 (19): 2486–97.
7. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. Eur. Heart J. Supplements 2007, 9 (Suppl. C) ISSN 1520– 765X/.
8. Isomaa B et al. Botnia study // Diabetes Care. – 2005; 683–689.
9. Reaven G. Role of insulin resistance in human disease // Diabetes. – 1988; 37: 1595 – 1607.
10. Shen S.J., Todaro J.F., Niaura R. et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X // Am. J. Epidemiol. 2003; 157: 701 – 711.
11. Standl E. Aetiology and consequences of the metabolic syndrome // Eur. Heart J. – 2005; 7(D): 10 – 13.
12. UKPDS Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients in type 2 diabetes (UKPDS 34)//BMJ 1998; 317: 703–13.
Review
For citations:
Kryuchkova I.V., Adamchik A.S. CARBOHYDRATE METABOLISM DISTURBANCES: THERAPEUTIC POTENTIAL IN METABOLIC SYNDROME. Russian Journal of Cardiology. 2009;(2):44-48. (In Russ.)
Views:
573
Email this article 